Organicell Regenerative Medicine, Inc   Report issue

For profit Phase 2
Founded: Miami FL United States (2011)

Organization Overview

First Clinical Trial
2020
NCT04384445
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer at Organicell Regenerative Medicine, Inc | Chief Science Officer at Organicell Regenerative Medicine, Inc | Co-Investigator | Organicell Regenerative Medicine

Active Ingredients

Drugs in Phase 2 Trials (3)

amniotic fluid (3 trials)

erucov-vac (1 trial)

organicell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Coronavirus Infections (Phase 2)

Infections (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3